Home How to Buy Moderna Shares Online in the UK
Kane Pepi
Fact Checked
Fact Checked
Everything you read on our site is provided by expert writers who have many years of experience in the financial markets and have written for other top financial publications. Every piece of information here is fact-checked.
Please note that we are not authorised to provide any investment advice. The information on this page should be construed for information purposes only. We may earn commissions from the products mentioned on this site.

Moderna is a US-based pharmaceutical company that specialises in biotechnology. Its main focus is on the development of vaccines – including that of COV-19.

Much like many other pharmaceutical companies that claim to be inching closer to a COV-19 vaccine, Moderna shares are booming in 2020. Although the stocks are listed in the US, making a purchase from the UK can be completed in less than 10 minutes when using the right broker.

In this guide, we’ll walk you through the process of how to buy Moderna shares online in the UK. On top of exploring the best UK share dealing sites to do this with, we’ll also run you through some background information on Moderna as a company.

Step 1: Find a UK Stock Broker to Buy Moderna Shares

Moderna is an American company that is publicly-listed on the NASDAQ. There are hundreds of UK-based brokers that give you unfettered access to this stock exchange, which is great.

However, you then need to consider other factors associated with your chosen platform – such as how much it charges to buy US-based shares and what payment methods are supported. And of course – your chosen broker needs to hold a license with the FCA.

To point you in the right direction, below you will find a small selection of stock brokers that allow you to buy Moderna shares online in the UK.

Step 2: Research Moderna Shares

Moderna shares have performed very well in 2020, largely because of its progress with a potential COV-19 vaccine. However, the biotechnology company isn’t the only firm active in the race to find a treatment – meaning that you need to consider the risks of making an investment.

In other words, if Moderna is unable to bring its vaccine to the wider markets – the value of your investment is likely to suffer greatly. With this in mind, you need to perform some broader research on the company before proceeding with a share purchase.

Below you will find some important considerations that you need to make to help clear the mist.

What is Moderna?

Launched as recently as 2010 – Moderna is a US-based biotechnology company that focuses on a specific niche on vaccine development. This is based on inserting mRNA into human cells with the view of developing immunity to a specific virus. Although the company went public in late 2018 – you might not have heard of it until recently.

This is because Moderna is one of many companies that is actively looking to develop a vaccine for COV-19. In fact, the firm was one of the first to begin trials. As of late July, Moderna entered phase three of its clinical trial process – which is evident in the speed in which its shares have increased over the past 10 months.

Moderna Share Price History

Moderna made the transition from a start-up to a fully-fledged PLC in just 8 years. It held its respective IPO in December 2018 – opting for the NASDAQ. The firm priced its shares at $23 each – which gave it an initial valuation of approximately $7.5 billion. This made it the most successful IPO for a biotechnology company in terms of the amount raised.

Moderna share price history

Fast forward to October 2020 and Moderna carries a market valuation of over $28 billion.  It is important to note that it hasn’t been all plain sailing for Moderna – as its share price remained somewhat flat until March 2020. This is, of course, when the firm announced that it was working on a vaccine for COV-19.

Since then, the shares have been on a strong upward trajectory. In fact, they hit highs of $95 in July – representing a YTD increase of almost 400%. At the time of writing, Moderna shares have tailed off slightly to $73, albeit, this still translates to 2020 gains over 280%.

Moderna Shares Dividend Information

If you are looking to add some dividend stocks to your investment portfolio – Moderna won’t be for. To date, it has never paid a dividend does not plan to do so for the foreseeable future. After all, not only is Moderna is still a young company – but it is investing most of its incoming cash flows into research and development.

Check out our page on the best dividend stocks of 2020 if you’re looking to invest in some income-generating companies.

Should I Buy Moderna Shares?

Make no mistake about it – investing in Moderna shares in this current economic climate is a high-risk gamble. This is because investor appetite is primarily focused on a vaccine for COV-19. Sure, the firm was one fo the first pharmaceutical entitles to begin clinal trials – which is a great sign.

However, there are dozens of other companies out there that also claim to be inching closer to a potential treatment. As such, if Moderna is not the one to reach this feat – it is all-but-certain that its share will move in the opposite direction. In fact, this is likely to be the case the very moment the markets get whim of a potential delay or regularly stumbling block.

Here’s what you need to know before you buy Moderna shares.

Everything Lies on its Phase 3 Results

As noted above, investors have been pumping money into Moderna shares because of its progress with its COV-19 vaccine trials. As it stands, the firm is now in the crucial stage of phase 3. We won’t know how the trial will pan out until Moderna publishes its results – which is imminent.

What we do know is that the FDA has already put a temporary hold on other clinical trials owing to concerns about safety. In particular, this includes biotechnology counterpart Inovio, as well as pharma-giant AstraZeneca.

Consistent Losses and a Major Drop in Revenue 

Putting the ongoing COV-19 clinical trials to one side momentarily, it is important to make reference to Moderna’s financials – which do anything but paint a good picture. For example, the firm has lost more than $200 million in each of its prior four quarters. This is monumental when you consider the firm’s market capitalisation.

Sure, Moderna is currently worth $7.5 billion, but it was valued at just a fraction of this figure this time last year. Additionally, stockholder should also be concerned about the sheer size of its revenue decline.

For example, while Moderna reported sales of $135 million in 2018, this figure stood at just $60 million in the following year. This represents a decline of 55%.


Moderna Shares Buy or Sell?

Buying Moderna shares is somewhat of a gamble – as much of your ability to make money is dependent on the firm’s phase 3 vaccine trials for COV-19. Crucially, this means that both the upside and downside potential is huge. Scenario 1 is that the results of phase 3 are positive – and the share price of Moderna follows suit. Scenario 2 is that the results were not as expected – or a regulatory hurdle comes into play. If this is the case, then expect the shares to drop – and quickly.

The Verdict?

Moderna shares offer a high-risk/high-return proportion. With this in mind, you are best to keep your stakes to a minimum. You can invest from just $50 when using our top-rate broker – which is about £40. In addition to this, the platform offers several other pharmaceutical stocks that are also working on a COV-19 vaccine.

Other Vaccine Shares

Interested in investing in other pharmaceutical companies that are involved in developing a coronavirus vaccine? Check out the list below.


What does Moderna do?

What stock exchange are Moderna shares listed on?

Do Moderna shares pay dividends?

How close is Moderna to a COV-19 vaccine?

How do you buy shares in Moderna in the UK?

Kane Pepi

Kane Pepi

Kane Pepi is a British researcher and writer that specializes in finance, financial crime, and blockchain technology. Now based in Malta, Kane writes for a number of platforms in the online domain. In particular, Kane is skilled at explaining complex financial subjects in a user-friendly manner. Academically, Kane holds a Bachelor’s Degree in Finance, a Master’s Degree in Financial Crime, and he is currently engaged in a Doctorate Degree researching the money laundering threats of the blockchain economy. Kane is also behind peer-reviewed publications - which includes an in-depth study into the relationship between money laundering and UK bookmakers. You will also find Kane’s material at websites such as MoneyCheck, the Motley Fool, InsideBitcoins, Blockonomi, Learnbonds, and the Malta Association of Compliance Officers.